type 2 diabetes

As Diabetes Explodes, Big Pharma Is Gearing Up

Diabetes is a growing global scourge, but for Big Pharma it's more of a lifesaver. As the number of people with diabetes and prediabetes explodes, drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes could be a $55 billion market by 2019.

The Number of Americans With Diabetes Is Projected to Soar

As many as one-third of American adults could develop diabetes in the next 40 years, according to a new analysis by the Centers for Disease Control and Prevention (CDC). Diabetes was the seventh leading cause of death in 2007, and it's the leading cause of new cases of blindness among adults under age 75, according to the CDC report. The disease is also among the most expensive chronic illnesses to treat, and is considered one of the culprits in rising health care costs.

FDA Panel Votes to Keep Avandia on Market

GlaxoSmithKline's diabetes drug Avandia has been found to have increased heart attack risk compared to other similar medication. But a majority of the Food and Drug Administration's panel of outside experts have voted to keep the drug on the market -- though new restrictions are likely.

Drug Approval Lifts Novo Nordisk, Amylin Stock

Federal regulators approved Novo Nordisk's new once-daily injection for treating Type 2 diabetes Victoza, driving shares higher. Shares of Amylin Pharmaceuticals also rallied as the approval of Victoza raises hopes that Amylin's rival drug will also get the greenlight.

Roche Diabetes Drug Makes Waves

The U.S. diabetes drug market just got a little more competitive. Swiss drugmaker Roche (RHHBY) said Wednesday an experimental medicine in late-stage development works better in treating type 2 diabetes than Merck (MRK) Januvia, according to a clinical study.